Related Experiment Video
Updated: Jun 19, 2026
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
Percutaneous ethanol injection before liver transplantation in the hepatocellular carcinoma
Fernanda Branco1, Concepció Brú, Ramon Vilana
1Department of Ultrasound and BCLC group Hospital Clinic of Barcelona, Liver Unit, Digestive Disease Institute, University of Barcelona, Postgraduate Program of Hepatology, Fundação Faculdade Federal de Ciências Médicas de Porto Alegre, Brazil. fsba@terra.com.br
Background/Objectives:
The study evaluates the outcome of patients who performed orthotopic liver transplantation (LT) as treatment for hepatocellular carcinoma (HCC), with percutaneous ethanol injection (PEI) while on the waiting list, verifying the effectiveness of this treatment in producing tumor necrosis and avoiding dropout and identifying treatment-related complications.
Material And Methods:
Medical records of 97 patients on the waiting list for LT at Hospital Clinic of Barcelona were examined. Sixty-two (56.3%) patients had been treated with PEI (group 1); 35 (31.8%) had not received any anti-tumor therapy before LT (group 2).
Results:
Complete necrosis of the tumor was observed in 38/59 (64.3%) patients. The presence of additional nodules in the explant and the diameter of the main tumor of group 1 was significantly lower than in group 2 (p = 0.002). Dropout related to tumor progression occurred in 4.8% and 8.5%, and tumor recurrence in 5% and 6.2% for groups 1 and 2, respectively. Major complications were not evidenced after 421 PEI sessions and there was no tumor implant in the needle traject.
Conclusions:
In conclusion, the percutaneous treatment of HCC with PEI is a safe and effective method before the LT.
